Decoding 4 Analyst Evaluations For Altimmune
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Express News | B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
Altimmune Analyst Ratings
Buy Rating on Altimmune: Pemvidutide's Market Potential in Obesity and Beyond
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript
Evercore ISI Remains a Buy on Altimmune (ALT)
Altimmune, Inc. (ALT): A Good GLP-1 and Weight Loss Stock to Buy Now?
Buy Rating Affirmed for Altimmune as Pemvidutide Poised to Lead NASH Treatment Market
Altimmune | 10-Q: Q2 2024 Earnings Report
Express News | Altimmune Shares Are Trading Higher. The Company Reported Q2 Financial Results
Express News | CORRECTION: Altimmune Q2 2024 GAAP EPS $(0.35) Misses $(0.34) Estimate, Sales $5.000K Down From $6.000K YoY
Earnings Flash (ALT) ALTIMMUNE Reports Q2 Revenue $5,000
Earnings Flash (ALT) ALTIMMUNE Reports Q2 Loss $-0.35 Per Share, Vs. Street Est of Loss $-0.35 Per Share
Altimmune GAAP EPS of -$0.35 Misses by $0.01
Express News | Altimmune Q2 Income From Operations USD -26.745 Million Vs. IBES Estimate USD -25.2 Million
Altimmune 2Q Loss/Shr 35c >ALT
Press Release: Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
Here Is the Next Potential Market Catalyst
Altimmune Q2 2024 Earnings Preview